GeNeuro SA

GNRO

CH0308403085

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-01-23 am EST			5-day change	1st Jan Change
0.0308 ^EUR	0.00%		-4.35%	-1.91%

Jan. 23	GeNeuro Requests Trading Halt on Euronext Paris Pending Debt Moratorium Ruling	MT
Jan. 23	GeNeuro Suspends Trading in Paris

GeNeuro Receives Debt-restructuring Moratorium from Swiss Court

Published on 05/28/2025 at 01:36 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about GeNeuro SA

Jan. 23	GeNeuro Requests Trading Halt on Euronext Paris Pending Debt Moratorium Ruling	MT
Jan. 23	GeNeuro Suspends Trading in Paris
25-10-15	GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report	CI
25-10-15	Geneuro SA postpones publication of half-yearly financial report	RE
25-09-29	GeNeuro Secures Debt-restructuring Moratorium Extension from Swiss Court	MT
25-09-26	Geneuro SA announces extension of its definitive Debt Restructuring moratorium	RE
25-08-19	Eclosion2 Fund Reduces Stake in Geneuro Below 10%
25-07-16	Court Orders GeNeuro Subsidiary's Liquidation	MT
25-06-13	GeNeuro Subsidiary Placed in Receivership Amid Group Restructuring	MT
25-06-12	Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas	RE
25-05-28	GeNeuro Receives Debt-restructuring Moratorium from Swiss Court	MT
25-01-13	Geneuro: Eclosion2 falls below 20%.
24-09-30	GeNeuro SA Decides to Postpone the Publication of its June 30, 2024 Half-Yearly Results	CI
24-09-20	Geneuro: presentation of new Temelimab data
24-07-15	GeNeuro to Apply for Debt Moratorium in Switzerland	MT
24-07-15	GeNeuro: a procedure to restructure debt
24-06-28	GeNeuro: failure of phase 2 study in Covid long
24-06-28	GeNeuro Announces Results of the Gnc-501 Study in Post-Covid-19 Syndrome	CI
24-05-16	GeNeuro SA Announces Last Patient Last Visit in Its Post-Covid Trial and Confirms Top-Line Results by End of June 2024	CI
24-03-20	Geneuro SA Announces Appointments of Board of Directors	CI
24-02-04	GeNeuro SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-02-02	GeNeuro: share price falls after private placement
24-02-02	GeNeuro Raises EUR5 Million from Share Issue	MT
24-01-08	GeNeuro appoints new Chief Medical Officer
24-01-05	Geneuro Sa Announces Executive Changes	CI

GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.

Employees

Sector

Biotechnology & Medical Research

Calendar

Apr. 05 - Q4 2025 Earnings Release (Projected)

More about the company